首页> 外文OA文献 >Analysis of A 6-Mirna Signature in Serum from Colorectal Cancer Screening Participants as Non-Invasive Biomarkers for Advanced Adenoma and Colorectal Cancer Detection
【2h】

Analysis of A 6-Mirna Signature in Serum from Colorectal Cancer Screening Participants as Non-Invasive Biomarkers for Advanced Adenoma and Colorectal Cancer Detection

机译:从结肠直肠癌筛查参与者中血清中6-miRNA签名的分析为未侵入性生物标志物,用于高级腺瘤和结肠直肠癌检测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Early detection of colorectal cancer (CRC) and its precancerous lesion, advanced adenomas (AA), is critical to improve CRC incidence and prognosis. Circulating microRNAs (miRNAs or miR) are promising non-invasive biomarkers for cancer detection. Our previous results showed that a plasma 6-miRNA signature (miR-15b-5p, miR-18a-5p, miR-29a-3p, miR-335-5p, miR-19a-3p and miR-19b-3p) could distinguish between CRC or AA and healthy individuals (controls). However, its diagnostic performance in serum is unknown. In this exploratory study we aim to evaluate the diagnostic performance of the 6-miRNA signature in serum samples in a cohort of individuals participating in Barcelona’s CRC Screening Programme. We prospectively collected serums from 264 faecal immunochemical test (FIT)-positive participants and total RNA was extracted. Finally, 213 individuals (CRC, 59, AA, 74, controls, 80) were included. MiRNA expression was quantified by real-time RT-qPCR and data analysis was performed by logistic regression. Faecal hemoglobin concentration (f(Hb)) from FIT of the same individuals was also considered. As previously described in plasma, serum from patients with AA or CRC presented significant differences in the 6-miRNA signature compared to controls. Moreover, when combined with f(Hb), the final signature showed high discriminative capacity to distinguish CRC from controls (area under the curve (AUC) = 0.88), and even AA (AUC = 0.81) that otherwise are poorly detected if we only consider f(Hb) (AUC = 0.64). Addition of the serum 6-miRNA signature to quantitative f(Hb) show high accuracy to detect patients with advanced colorectal neoplasia in average-risk individuals. A combination of these two non-invasive methods could be a good strategy to improve diagnostic performances of current CRC screening programmes.
机译:早期发现结直肠癌(CRC)及其癌前病变,进展期腺瘤(AA),是提高CRC的发病率和预后的关键。循环微RNA(miRNA或miR)是有前途的用于癌症检测的非侵入性生物标记物。我们以前的结果表明,等离子体6-miRNA特征(MIR-15B-5P,的miR-18A-5P,的miR-29A-3P,的miR-335-5p,的miR-19A-3P和miR-19b中-3P)可以区分CRC或AA和健康人(对照组)之间。然而,在血清中的诊断性能是未知的。在这种探索性研究我们的目标是在参加巴塞罗那的大肠癌筛查项目群体的队列研究,以评估血清样品中6-miRNA特征的诊断性能。我们前瞻性从264粪便免疫化学试验(FIT)阳性参与者收集的血清和提取总RNA。最后,213名个人(CRC,59,AA,74,控制装置,80)都包括在内。 miRNA的表达通过实时RT-qPCR定量并通过逻辑回归进行数据分析。从同一个体的粪便FIT血红蛋白浓度(F(HB))也被考虑。如先前在等离子体所描述的,来自患有AA或CRC血清呈现与对照相比,在6-miRNA特征显著差异。此外,当以f(HB)组合,最终的签名表明,否则在检测到差的(曲线下面积(AUC)= 0.88)高辨别能力与对照区分CRC,甚至AA(AUC = 0.81),如果我们仅考虑F(HB)(AUC = 0.64)。血清6-miRNA标识以定量F(HB)的加入显示出高精度地检测患者的平均风险个体晚期大肠癌的肿瘤。这两种非侵入性方法的组合可能是改善目前大肠癌筛查项目的诊断表演一个很好的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号